These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 17113177)

  • 1. Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors.
    Ho EA; Soo PL; Allen C; Piquette-Miller M
    J Control Release; 2007 Jan; 117(1):20-7. PubMed ID: 17113177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
    Vassileva V; Grant J; De Souza R; Allen C; Piquette-Miller M
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):907-14. PubMed ID: 17375303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo characterization of a novel biocompatible polymer-lipid implant system for the sustained delivery of paclitaxel.
    Ho EA; Vassileva V; Allen C; Piquette-Miller M
    J Control Release; 2005 May; 104(1):181-91. PubMed ID: 15866344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting.
    Lu H; Li B; Kang Y; Jiang W; Huang Q; Chen Q; Li L; Xu C
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):175-81. PubMed ID: 16718469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo.
    Yang X; Feng Y; Gao Y; Shen J; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z
    Gynecol Oncol; 2015 Apr; 137(1):134-42. PubMed ID: 25677062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice.
    Harper E; Dang W; Lapidus RG; Garver RI
    Clin Cancer Res; 1999 Dec; 5(12):4242-8. PubMed ID: 10632366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells.
    Yadav S; van Vlerken LE; Little SR; Amiji MM
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):711-22. PubMed ID: 18618115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
    George JA; Chen T; Taylor CC
    Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux.
    Chavanpatil MD; Patil Y; Panyam J
    Int J Pharm; 2006 Aug; 320(1-2):150-6. PubMed ID: 16713148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for paclitaxel.
    Danhier F; Magotteaux N; Ucakar B; Lecouturier N; Brewster M; Préat V
    Eur J Pharm Biopharm; 2009 Oct; 73(2):230-8. PubMed ID: 19577643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanohybrid systems of non-ionic surfactant inserting liposomes loading paclitaxel for reversal of multidrug resistance.
    Ji X; Gao Y; Chen L; Zhang Z; Deng Y; Li Y
    Int J Pharm; 2012 Jan; 422(1-2):390-7. PubMed ID: 22001531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91.
    Sugimoto Y; Tsukahara S; Sato S; Suzuki M; Nunoi H; Malech HL; Gottesman MM; Tsuruo T
    J Gene Med; 2003 May; 5(5):366-76. PubMed ID: 12731085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
    Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
    Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of docetaxel in paclitaxel-resistant ovarian cancer cells.
    Sato S; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Iba T; Naniwa J; Uegaki K; Terakawa N
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):247-52. PubMed ID: 14610615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydrotropic oligomer-conjugated glycol chitosan as a carrier of paclitaxel: synthesis, characterization, and in vivo biodistribution.
    Saravanakumar G; Min KH; Min DS; Kim AY; Lee CM; Cho YW; Lee SC; Kim K; Jeong SY; Park K; Park JH; Kwon IC
    J Control Release; 2009 Dec; 140(3):210-7. PubMed ID: 19560497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral delivery of paclitaxel using a thermosensitive hydrogel in human tumor xenografts.
    Kim JH; Lee JH; Kim KS; Na K; Song SC; Lee J; Kuh HJ
    Arch Pharm Res; 2013 Jan; 36(1):94-101. PubMed ID: 23371803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
    Gelderblom H; Verweij J; van Zomeren DM; Buijs D; Ouwens L; Nooter K; Stoter G; Sparreboom A
    Clin Cancer Res; 2002 Apr; 8(4):1237-41. PubMed ID: 11948138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of ovarian cancer growth and implantation by paclitaxel after laparoscopic surgery in a mouse model.
    Lee CL; Kay N
    Am J Obstet Gynecol; 2006 Nov; 195(5):1278-81. PubMed ID: 17014818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.